151 related articles for article (PubMed ID: 33353557)
1. Germline variation of Ribonuclease H2 genes in ovarian cancer patients.
Polaczek R; Schürmann P; Speith LM; Geffers R; Dürst M; Hillemanns P; Park-Simon TW; Liebrich C; Dörk T
J Ovarian Res; 2020 Dec; 13(1):146. PubMed ID: 33353557
[TBL] [Abstract][Full Text] [Related]
2. Epithelial RNase H2 Maintains Genome Integrity and Prevents Intestinal Tumorigenesis in Mice.
Aden K; Bartsch K; Dahl J; Reijns MAM; Esser D; Sheibani-Tezerji R; Sinha A; Wottawa F; Ito G; Mishra N; Knittler K; Burkholder A; Welz L; van Es J; Tran F; Lipinski S; Kakavand N; Boeger C; Lucius R; von Schoenfels W; Schafmayer C; Lenk L; Chalaris A; Clevers H; Röcken C; Kaleta C; Rose-John S; Schreiber S; Kunkel T; Rabe B; Rosenstiel P
Gastroenterology; 2019 Jan; 156(1):145-159.e19. PubMed ID: 30273559
[TBL] [Abstract][Full Text] [Related]
3. Contributions of the two accessory subunits, RNASEH2B and RNASEH2C, to the activity and properties of the human RNase H2 complex.
Chon H; Vassilev A; DePamphilis ML; Zhao Y; Zhang J; Burgers PM; Crouch RJ; Cerritelli SM
Nucleic Acids Res; 2009 Jan; 37(1):96-110. PubMed ID: 19015152
[TBL] [Abstract][Full Text] [Related]
4. Depletion of RNASEH2 Activity Leads to Accumulation of DNA Double-strand Breaks and Reduced Cellular Survivability in T Cell Leukemia.
Ghosh D; Kumari S; Raghavan SC
J Mol Biol; 2022 Jun; 434(12):167617. PubMed ID: 35500843
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ribonucleotide content in the genomic DNA of ribonuclease H2 A subunit (RH2A)-knockout NIH3T3 cells after transient expression of wild-type RH2A or RH2A variants with an Aicardi-Goutières syndrome-causing mutation.
Kandabashi M; Yano H; Hara H; Ogawa S; Kamoda K; Ishibashi S; Himeda K; Baba M; Takita T; Yasukawa K
J Biochem; 2022 Sep; 172(4):225-231. PubMed ID: 35791750
[TBL] [Abstract][Full Text] [Related]
6. High-risk epithelial ovarian cancer patients for hereditary ovarian cancer.
Chirasophon S; Manchana T; Teerapakpinyo C
J Obstet Gynaecol Res; 2017 May; 43(5):929-934. PubMed ID: 28188963
[TBL] [Abstract][Full Text] [Related]
7. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
8. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
9. Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications.
Xiao X; Melton DW; Gourley C
Gynecol Oncol; 2014 Feb; 132(2):506-12. PubMed ID: 24333356
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
11. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of ribonuclease H2 C subunit-knockout NIH3T3 cells.
Hara H; Yano H; Akazawa K; Kamoda K; Kandabashi M; Baba M; Takita T; Yasukawa K
Biosci Biotechnol Biochem; 2023 Jul; 87(8):865-876. PubMed ID: 37291694
[TBL] [Abstract][Full Text] [Related]
13. Defects in RNase H2 Stimulate DNA Break Repair by RNA Reverse Transcribed into cDNA.
Keskin H; Storici F
Microrna; 2015; 4(2):109-16. PubMed ID: 26456534
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
15. Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair.
Ghodgaonkar MM; Lazzaro F; Olivera-Pimentel M; Artola-Borán M; Cejka P; Reijns MA; Jackson AP; Plevani P; Muzi-Falconi M; Jiricny J
Mol Cell; 2013 May; 50(3):323-32. PubMed ID: 23603115
[TBL] [Abstract][Full Text] [Related]
16. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
[TBL] [Abstract][Full Text] [Related]
17. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
18. Epithelial ovarian cancer risk: A review of the current genetic landscape.
Flaum N; Crosbie EJ; Edmondson RJ; Smith MJ; Evans DG
Clin Genet; 2020 Jan; 97(1):54-63. PubMed ID: 31099061
[TBL] [Abstract][Full Text] [Related]
19. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
Permuth-Wey J; Fulp WJ; Reid BM; Chen Z; Georgeades C; Cheng JQ; Magliocco A; Chen DT; Lancaster JM
Int J Cancer; 2016 Feb; 138(3):612-9. PubMed ID: 26264211
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
